Skip to main content
OpenTrials
Completed

NCT Number: NCT02284295

Molecular, Cytological Features and Genetic Susceptibility of COPD Attributable to Different Environmental Exposures 2

The objective of this study is to investigate molecular, cytological and genetic features of occupational chronic obstructive pulmonary disease (COPD) in conditions of different occupational exposures. In order to achieve this goal serum pro-inflammatory cytokines and standard inflammation markers level, hemostasis, cytological analysis of bronchoalveolar lavage fluid and association of single nucleotide polymorphisms (SNPs) rs1800470 transforming growing factor β1 (TGF β1) gene, rs1828591 hedgehog interacting protein (HHIP) gene, rs4129267 interleukin 6 receptor (IL-6R) gene, rs1051730 nicotinic acetylcholine receptor 3 (CHRNA3) gene with COPD in subjects exposed to silica dust and in those exposed to polycyclic aromatic hydrocarbons exhaust will be investigated. The relationship between genotype and phenotype characteristics, such as an inflammation activity, assessed by C-reactive protein (hsCRP) and tumor necrosis factor alpha (TNF α) serum concentration, in different occupational COPD groups will be studied. The hypothesis is that the mechanisms underlying disease development and progression are different due to environmental risk factor that reflex in differs in disease attributes - molecular biomarkers, cytology results and genetic susceptibility between COPD due to dust, COPD due to chemicals and COPD in smokers therefore COPD can be subdivided into ecological phenotypes according to environmental risk factor.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–75 year

Sex eligibility

Male

Study type

Observational

Primary location

Novosibirsk City Hospital #2

Novosibirsk, 630084, Russia

About this study

Study rationale: The main risk factors of COPD are tobacco smoking, biomass smoking and occupational factors. Tobacco smoking is well-known risk factor so tobacco induced COPD is completely established. Nevertheless the meaning of occupational factors which are less famous are equally important. Based on comprehensive literature review ATS endorsed the notion that strong evidence implicates occupational factors as cause of COPD. Occupational COPD takes 19.2 % of all COPD patients and 31.1 % of never smokers as resulted NHANESIII study. A considerable number of work-related factors have evidence for a causal association with COPD including (and of course not limited) silica and silicates and aromatic hydrocarbons. Individuals in a variety of occupations and industries such as coal miners, painters, coke workers, tunnel workers, metallurgists, welding workers, transportation workers, builders, farmers are exposed to factors cited above. Despite this the clinical and pathophysiological features of COPD caused by occupational factors are still unclear.

Occupational factors leading airflow limitation are various entities - vapors, dusts, gases and fumes with different physical, chemical, biological and other features, so the mechanisms underlying disease development and progression may be different attributable to risk factor.

An environmental risk factors exposure as well as tobacco smoking results in COPD only in part of the subjects which indicates the significant genome and gene environmental interactions role. COPD develops in predisposed subjects undergoing risk factors exposure. Therefore the risk of COPD is individual and depends on both genetic and environments. There are few data concerning the effects of genetic on COPD risk in this specific subgroup - people who are exposed to occupational risk factors related to the certain environmental factor.

Statistical analysis: Statistical analysis will be carried out by Statistica 9.0 software. Significance level will be considered p = 0.05. The qualitative variables will be expressed as counts and percentages. The quantitative continuous variables will be expressed as means and standard error of means (M ± m) for variables that meet the criteria of normality and minimum and maximum, median for those that do not meet the criteria of normality. Kruskal-Wallis test will be used for comparing multiply independent samples and Mann-Whitney U test for comparing two independent samples if variable under consideration will continuous and that it will be measured on an ordinal scale. For comparisons of proportions, the Chi-square will be used.

For associations assessment we will use logistic regression method. The odds ratios (OR) and 95% confidence intervals (CI) will be calculated for each professional group. Multiple regression model will be used to explore the relationships between demographic characteristics, cytokine concentrations, hemostasis and airflow limitation in professional groups.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Post- bronchodilator forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) ratio less than 0.7
  • Stable phase of COPD
  • History of exposure to respirable silica dust, nonsmokers with no of passive exposure of tobacco smoke or history of exposure to aromatic hydrocarbons, nonsmokers with no of passive exposure of tobacco smoke or current tobacco smokers without history of occupational exposure
  • COPD risk factor exposure (occupational or tobacco smoke) duration not less than 12 months
  • Male
  • Caucasian
  • Age of 40 - 75 years old

Exclusion criteria

  • history of biomass smoke exposure
  • age less than 40 and above 75 years old
  • current COPD exacerbation
  • concomitant asthma
  • tuberculosis and other pulmonary diseases
  • allergic and autoimmune disorders
  • active infections
  • immunodeficiency, including HIV infection
  • parasitological diseases
  • malignancies
  • lack of informed consent.

Treatment and study plan

exposure to respirable silica dust

Other

History of exposure to respirable silica dust due to job

exposure to aromatic hydrocarbons

Other

history of exposure to aromatic hydrocarbons due to job

Primary outcomes

  1. Difference in serum interleukin 1 beta (IL-1β) level between COPD patients exposed to dust, chemicals and tobacco smoke

    Time frame: 1 day (a single measurement)

    Comparison of groups

  2. Difference in serum tumor necrosis factor alpha (TNFα) level between COPD patients exposed to dust, chemicals and tobacco smoke

    Time frame: 1 day (a single measurement)

    Comparison of groups

  3. Difference in spontaneous thrombocyte aggregation between COPD patients exposed to dust, chemicals and tobacco smoke

    Time frame: 1 day (a single measurement)

    Comparison of groups

  4. Difference in collagen induced thrombocyte aggregation between COPD patients exposed to dust, chemicals and tobacco smoke

    Time frame: 1 day (a single measurement)

    Comparison of groups

  5. Difference in epinephrine induced thrombocyte aggregation between COPD patients exposed to dust, chemicals and tobacco smoke

    Time frame: 1 day (a single measurement)

    Comparison of groups

  6. Difference in adenosine diphosphate induced thrombocyte aggregation between COPD patients exposed to dust, chemicals and tobacco smoke

    Time frame: 1 day (a single measurement)

    Comparison of groups

  7. Difference in fibrinogen level between COPD patients exposed to dust, chemicals and tobacco smoke

    Time frame: 1 day (a single measurement)

    Comparison of groups

  8. Difference in fibrinogen degradation products level between COPD patients exposed to dust, chemicals and tobacco smoke

    Time frame: 1 day (a single measurement)

    Comparison of groups

  9. Difference in D-dimer level between COPD patients exposed to dust, chemicals and tobacco smoke

    Time frame: 1 day (a single measurement)

    Comparison of groups

  10. Difference in serum endothelin1 level between COPD patients exposed to dust, chemicals and tobacco smoke

    Time frame: 1 day (a single measurement)

    Comparison of groups

  11. Difference in serum nitric oxide level between COPD patients exposed to dust, chemicals and tobacco smoke

    Time frame: 1 day (a single measurement)

    Comparison of groups

  12. Differences in cytological analysis of bronchoalveolar lavage fluid results between COPD patients exposed to dust, chemicals and tobacco smoke

    Time frame: 1 day (a single measurement)

    Comparison of groups

  13. Association of SNPs rs1800470 TGF β1 gene, rs1828591 HHIP gene, rs4129267 IL-6R gene, rs1051730 CHRNA3 gene with COPD in subjects exposed to dust and in those exposed to chemicals. (Odds ratio and 95% confidence interval)

    Time frame: 1 day (a single measurement)

    Odds ratio and 95% confidence interval will be calculated for each occupational group. Controls - healthy people.

Secondary outcomes

  1. Relationship between genotype and phenotype characteristics, such as an inflammation activity, assessed by hsCRP and TNF α serum concentration, in different occupational COPD groups.

    Time frame: 1 day (a single measurement)

    For SNPs that will occur associated with occupational COPD differences in hsCRP and TNFα serum concentration between subjects with different genotypes will be established separately for exposed to dust COPD group and for exposed to chemicals COPD group.

Sponsors and collaborators

Lead sponsor

Novosibirsk City Hospital #2

Other

Collaborators

  • Siberian Branch of the Russian Academy of Medical Sciences

Registry information

Official study title

Molecular, Cytological Features and Genetic Susceptibility of Occupational Chronic Obstructive Pulmonary Disease Attributable to Different Environmental Exposures 2.

Important dates

Study start
2014
Primary completion
2014
Study completion
2014
First posted
Nov 6, 2014
Registry last updated
Apr 14, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.